A room full of automation devices containing the CellScrew®

We are redefining the manufacturing of adherent cells.

Being the world's first company that produces labware from plant-based plastic, we empower the biopharmaceutical industry to embrace sustainability. Through pioneering systems like the CellScrew®, we aim to address the bottleneck in biopharmaceutical production by enhancing production capacity, ultimately increasing patient access and affordability to life-changing novel therapies.

Impact

About Green Elephant Biotech

Green Elephant Biotech was founded in 2021 by Dr. Joel Eichmann and Felix Wollenhaupt. Since then, our team has grown to include diverse team members with expertise in bioprocessing, business development, and marketing. We're a passionate and diverse team of highly motivated young professionals, driven to build a sustainable future by revolutionizing the biotech and pharma industry.

The Green Elephant team walks towards the camera

Our locations

Gießen

The CellScrew® on a lab bench with someone pipetting

Giessen is where it all began for us. Here, our R&D team works on developing new sustainable products, and our Quality Management team ensures compliance with the relevant regulations. Our flagship product, the CellScrew®, is manufactured on-site in our production facilities.

Kerkrader Straße 9

35394 Gießen

Berlin

Our Berlin office manages the business operations. The Sales and Marketing team promote the company and our sustainable products. We maintain close communication with customers, business partners, and our R&D team.

Prenzlauer Allee 36 G

10405 Berlin

Our contribution to the Sustainable Development Goals

A seamless pipeline from biopharma research and development to manufacturing is crucial in delivering life-saving treatments to patients cost-effectively and within a short time-to-market.

Our CellScrew® product is built on the idea of empowering the biopharmaceutical industry to operate more sustainably and efficiently. With our innovative solutions, we aim to overcome the challenge of limited production capacity in the biopharmaceutical sector by introducing an easily adoptable cell culture system that maximizes productivity.